Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Bayer is the lead sponsor of 53 current clinical trials in our USA, UK, China, India, Ireland and EU (CTIS) registers. 24 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Darolutamide, Finerenone and Pembrolizumab. The most-studied condition is Chronic Kidney Disease.

Company profile on this site (news, sites, medicines, approvals): Bayer AG (DE) →

ClinicalTrials.gov trials by status

Recruiting2449%
Not yet open510%
Active, closed2041%

Trials by phase

Observational2041%
Phase 11020%
Phase 3816%
Phase 2510%
Phase 1/236%
Phase 424%
Not applicable12%

Clinical trials sponsored by Bayer

49 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy NCT06854640 · Sepsis, Coagulopathy Drug: BAY3389934	Phase 1	Recruiting	2025-03	USA
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria NCT05457283 · Chronic Kidney Disease, Proteinuria, Children Drug: Finerenone	Phase 3	Recruiting	2022-11	UK, USA, India
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body NCT04142437 · Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion Drug: Larotrectinib	Observational	Recruiting	2020-04	Ireland, UK, USA, China
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) NCT06452277 · Advanced Non-small Cell Lung Cancer, HER2 Mutation Drugs: Carboplatin, Cisplatin, Pembrolizumab	Phase 3	Recruiting	2024-08	UK, USA, China
First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) NCT06217822 · Advanced Metastatic Castration-resistant Prostate Cancer, Prostate Specific Membrane Antigen (PSMA) Expression	Phase 1	Recruiting	2024-03	UK, USA
A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) NCT05348876 · ClinicalTrials.gov ↗ · Non-metastatic Castration-resistant Prostate Cancer Drug: Darolutamide	Phase 4	Recruiting	2022-08	India
A Study to Learn About How Safe BAY3389934 is and How it Affects Blood Clotting When Given Alone or With Aspirin in Healthy Participants NCT07652723 · Drug-drug Interaction Drugs: Aspirin, BAY3389934	Phase 1	Recruiting	2026-05	USA
A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation NCT06659341 · Advanced Solid Tumors Harboring KRAS G12C Mutation	Phase 1	Recruiting	2024-11	UK
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) NCT06760819 · ClinicalTrials.gov ↗ · Advanced Solid Tumors, HER2 Mutation	Phase 2	Recruiting	2025-02	USA, China
A Study to Understand How Cardiac Surgery-associated Acute Kidney Injury Develops in Participants Who Undergo Heart Surgery With the Use of Heart-lung Machine NCT06772025 · Cardiac Surgery-associated Acute Kidney Injury	Not applicable	Recruiting	2025-02	UK
A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation NCT07535112 · Advanced/Metastatic Colorectal Adenocarcinoma Drug: Cetuximab	Phase 1	Recruiting	2026-04	USA
A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer. NCT07450599 · ClinicalTrials.gov ↗ · High-risk Localized Prostate Cancer Drug: Darolutamide	Phase 2	Recruiting	2026-04	China
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction NCT07192952 · ClinicalTrials.gov ↗ · Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric) Drug: Finerenone	Phase 3	Recruiting	2026-06	UK, USA
An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK) NCT06315556 · ClinicalTrials.gov ↗ · Retinopathy of Prematurity, Preterm Infants Drugs: Aflibercept, Eylea	Observational	Recruiting	2024-03	UK
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction NCT07188805 · ClinicalTrials.gov ↗ · Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric) Drug: Finerenone	Phase 3	Recruiting	2025-11	UK, USA
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors NCT06914128 · ClinicalTrials.gov ↗ · MTAP-deleted Solid Tumors	Phase 1/2	Recruiting	2025-03	UK, USA, China
A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer NCT06764316 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 1	Recruiting	2025-02	UK, USA, China
A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation NCT07625215 · ClinicalTrials.gov ↗ · Atrial Fibrillation	Phase 2	Recruiting	2026-08	USA
A Study to Learn About Heart-Related Risks in Elderly Men With Advanced Prostate Cancer Treated With Enzalutamide or Darolutamide NCT07672119 · ClinicalTrials.gov ↗ · Prostate Cancer	Observational	Recruiting	2026-06	USA
A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications NCT07330258 · ClinicalTrials.gov ↗ · Parkinson's Disease	Observational	Recruiting	2026-07	USA
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) NCT05099172 · ClinicalTrials.gov ↗ · Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation	Phase 1/2	Recruiting	2021-10	USA, China
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics NCT07406282 · ClinicalTrials.gov ↗ · Prostatic Neoplasms, Metastatic Hormone-Sensitive Prostate Cancer Drugs: Abiraterone acetate, Apalutamide, Darolutamide	Observational	Recruiting	2025-07	USA
An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions NCT06278207 · ClinicalTrials.gov ↗ · Chronic Kidney Disease, Type 2 Diabetes Mellitus Drug: Finerenone	Observational	Recruiting	2024-05	USA
An Observational Study Conducted in China to Evaluate the Efficacy and Safety of Darolutamide in Combination With Androgen Deprivation Therapy (ADT) for Men With Non-metastatic Prostate Cancer That Progressed Following Prior Bicalutamide + ADT Treatment NCT07538843 · ClinicalTrials.gov ↗ · Non-metastatic Castration-resistant Prostate Cancer	Observational	Recruiting	2026-07	China
Post Approval Observational Study to Learn More About How Safe Octocog Alfa is and How Well it Works in Patients With Severe Hemophilia A in India NCT07446010 · Hemophilia A	Observational	Not yet open	2026-09	India
A Study of Darolutamide Plus Androgen Deprivation Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer in India NCT07806591 · ClinicalTrials.gov ↗ · Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Drug: Darolutamide	Observational	Not yet open	2026-10	India
An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health NCT05477953 · ClinicalTrials.gov ↗ · Chagas Disease	Observational	Not yet open	2026-12	USA
Phase 1 Study in Healthy Adults to See How Sevabertinib Changes Metformin Levels in the Body NCT07753252 · ClinicalTrials.gov ↗ · Healthy Participants Drugs: Metformin, Sevabertinib	Phase 1	Not yet open	2026-08	USA
An Observational Study to Learn How Mirena and Other Progestogen Treatments Are Used for Endometrial Protection in Women 40+ With a Uterus in the United States Receiving Estrogen Therapy, and Their Respective Health Outcomes NCT07795606 · ClinicalTrials.gov ↗ · Estrogen Therapy	Observational	Not yet open	2026-08	USA
A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children NCT02637687 · Solid Tumors Harboring NTRK Fusion Drug: Larotrectinib	Phase 1/2	Active, closed	2015-12	Ireland, UK, USA, China
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria NCT05196035 · ClinicalTrials.gov ↗ · Chronic Kidney Disease, Proteinuria Drug: Finerenone	Phase 3	Active, closed	2022-03	UK, USA, India
The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema NCT06075147 · Visual Impairment, Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macula Edema (DME) Drug: Aflibercept	Observational	Active, closed	2024-02	UK
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer NCT05587296 · ClinicalTrials.gov ↗ · Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes	Phase 3	Active, closed	2022-10	Ireland, UK
An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice NCT06763146 · ClinicalTrials.gov ↗ · Chronic Kidney Disease, Type 2 Diabetes Mellitus Drug: Finerenone	Observational	Active, closed	2025-09	India
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors NCT05537740 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Drug: Pembrolizumab	Phase 1	Active, closed	2022-10	UK, USA, China
A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome NCT07211685 · ClinicalTrials.gov ↗ · Alport Syndrome	Phase 2	Active, closed	2025-11	UK, USA, India, China
An Observational Study to Learn More About How Safe Vericiguat is and How Well it Works in Indian People With Chronic Heart Failure With Reduced Ejection Fraction and Worsening Chronic Heart Failure Under Real World Conditions NCT06632483 · ClinicalTrials.gov ↗ · Chronic Heart Failure With Reduced Ejection Fraction, Worsening Chronic Heart Failure Drug: Vericiguat	Observational	Active, closed	2025-09	India
A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors NCT05614102 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Drug: Pembrolizumab	Phase 1	Active, closed	2022-11	UK, USA, China
A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice NCT07344779 · ClinicalTrials.gov ↗ · Metastatic Hormone-Sensitive Prostate Cancer Drugs: Darolutamide, Docetaxel	Observational	Active, closed	2026-01	UK
RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer) NCT04597125 · ClinicalTrials.gov ↗ · Metastatic Castrate Resistant Prostate Cancer (mCRPC)	Phase 4	Active, closed	2020-11	UK
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer NCT04464226 · ClinicalTrials.gov ↗ · Cancer Drug: Darolutamide	Phase 3	Active, closed	2020-10	UK, USA, China
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies NCT05794906 · ClinicalTrials.gov ↗ · Biochemically Recurrent Prostate Cancer Drug: Darolutamide	Phase 3	Active, closed	2023-04	UK, USA, China
A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) NCT06052306 · ClinicalTrials.gov ↗ · Metastatic Castration-resistant Prostate Cancer	Phase 1	Active, closed	2023-09	UK
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery NCT06117891 · ClinicalTrials.gov ↗ · Unresectable Hepatocellular Carcinoma Drugs: Atezolizumab, Bevacizumab, Durvalumab	Observational	Active, closed	2023-11	USA, China
An Observational Study in the United States to Learn How Venous Thromboembolism, Disseminated Intravascular Coagulation, and Sepsis Are Related NCT06765681 · ClinicalTrials.gov ↗ · Sepsis, Venous Thromboembolism, Disseminated Intravascular Coagulation	Observational	Active, closed	2025-01	USA
A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting NCT05348733 · ClinicalTrials.gov ↗ · Chronic Kidney Disease, Type 2 Diabetes Mellitus	Observational	Active, closed	2022-06	USA, China
A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described NCT04122976 · ClinicalTrials.gov ↗ · Prostate Cancer Drug: Darolutamide	Observational	Active, closed	2020-01	USA, China
Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A NCT03932201 · ClinicalTrials.gov ↗ · Hemophilia A	Observational	Active, closed	2019-10	USA
A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies NCT06246643 · ClinicalTrials.gov ↗ · Solid Malignant Tumors Drug: Regorafenib	Phase 2	Active, closed	2024-01	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Bayer in the EU trials register (CTIS)

4 trials

Authorised or ongoing trials in the EU Clinical Trials Information System with Bayer as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

Study	Phase	Status	Countries
[22961] A placebo-controlled, parallel-group, double blind, randomized, multi-cohort Phase 2 study to investigate efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of BAY 3670549 in adult participants with atrial fibrillation. 2025-523807-31-00 · Cardiovascular Diseases	Phase 2	Ongoing	Belgium, Netherlands, Germany + 4 more
(22597) A study to learn about how safe nitroglycerin is and how it affects the body when taken along with nurandociguat in people with coronary artery disease. 2025-522335-34-00 · CTIS ↗ · Cardiovascular Diseases	Phase 1	Authorised	Germany, Bulgaria
(21467) A Phase 3, single-arm, open-label extension study to evaluate the safety of finerenone in addition to standard of care, in pediatric heart failure patients, from birth to 18 years of age, with left ventricular systolic dysfunction (LVSD) 2024-519830-22-00 · CTIS ↗ · Cardiovascular Diseases Drug: Finerenone	Phase 3	Ongoing	Czechia, Germany, Greece + 10 more
A study to learn how safe nurandociguat is when taken with sildenafil in men with arterial hypertension. 2025-522336-14-00 · CTIS ↗ · Cardiovascular Diseases	Phase 1	Authorised	Germany

Drugs in Bayer trials

24 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Conditions in Bayer trials

53 conditions

Chronic Kidney Disease5 Advanced Solid Tumors3 Type 2 Diabetes Mellitus3Proteinuria2Left Ventricular Systolic Dysfunction2Heart Failure (Pediatric)2Metastatic Hormone-Sensitive Prostate Cancer2Sepsis2 Prostate Cancer2HER2 Mutation2Hemophilia A2Non-metastatic Castration-resistant Prostate Cancer2Solid Tumors Harboring NTRK Fusion1Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion1Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer1Hot Flashes1Advanced Non-small Cell Lung Cancer, HER2 Mutation1Children1Advanced Metastatic Castration-resistant Prostate Cancer1Prostate Specific Membrane Antigen (PSMA) Expression1Visual Impairment1Neovascular Age-related Macular Degeneration (nAMD)1Diabetic Macula Edema (DME)1Advanced Solid Tumors Harboring KRAS G12C Mutation1

By trial register

Register	Trials	Recruiting
Clinical trials in USA	33	18
Clinical trials in UK	23	11
Clinical trials in China	18	8
Clinical trials in India	8	2
Clinical trials in Ireland	3	1
EU register (CTIS)	4	—

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Chronic Kidney Disease

Sponsor	Trials
Shandong Suncadia Medicine	2
Shenzhen Salubris Pharmaceuticals	2
Prokidney	1
Yuanjun Yang	1

Sponsors with the most current trials registered for this condition.

Questions about Bayer trials

How many clinical trials does Bayer sponsor?

Bayer is the lead sponsor of 49 current trials on ClinicalTrials.gov in our USA, UK, China, India and Ireland registers, and 4 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Bayer trials recruiting?

Yes. 24 of its 49 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Bayer testing?

Its current trials name 24 drugs and biologicals as interventions. The most frequent are Darolutamide (8), Finerenone (7), Pembrolizumab (3), Aflibercept (2) and BAY3389934 (2). The number in brackets is how many of its trials name each drug.

Does Bayer have clinical trials in Ireland?

Yes. 3 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Bayer clinical trials